IPECAD Open-Source Model Framework
The IPECAD Open-Source Model Framework is a tool designed to evaluate the health and economic impact of treatments for early Alzheimer’s disease. It helps researchers and decision makers check the results of other models, test different assumptions, and improve transparency in decisions about funding new treatments.
At a glance
Use when
Evaluating cost-effectiveness of early Alzheimer’s treatments, conducting model validation, or performing sensitivity analyses on methodological assumptions in HTA.
Avoid when
When a highly individual-level simulation (e.g., microsimulation) is required, or when disease dynamics cannot be adequately represented by a categorized composite domain.
Inputs
Clinical trial data on treatment efficacy, natural disease progression parameters, utility values, cost inputs, treatment effect waning rates, stopping rules, and patient demographics.
Outputs
Incremental life-years, quality-adjusted life-years (QALYs), cost differences, and cost-effectiveness outcomes under various scenarios.
How it works
IPECAD is a cohort state-transition model using a categorized composite domain (cognition and function) for health-economic evaluation of early Alzheimer’s disease treatments. Developed in R, with spreadsheet and web-based versions, it supports cross-validation against models like ICER and AD-ACE. The framework enables sensitivity analyses on treatment effect waning, stopping rules, natural disease progression, and trial efficacy outcomes. Version 2 is open-source and available via GitHub for transparency and reproducibility in HTA submissions.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Assumptions
- Disease progression follows a categorized composite domain of cognition and function; treatment effects may wane over time; patients discontinue treatment based on defined stopping rules; long-term outcomes are extrapolated from short-term trial data.
- Strengths
- Open-source availability enhances transparency and reproducibility,Supports cross-validation with established models (e.g., ICER, AD-ACE),Flexible structure allows testing of multiple uncertainty scenarios,Available in multiple formats (R, spreadsheet, web-based)
- Limitations
- Results are sensitive to key assumptions such as waning efficacy and stopping rules,Relies on short-term trial data for long-term projections,May not capture all heterogeneity in patient populations
- Also known as
- IPECAD model, IPECAD framework, IPECAD version 2
Questions this answers
- › What is the incremental clinical and economic value of early Alzheimer’s disease treatments?
- › How do different modeling assumptions affect cost-effectiveness results?
- › How can existing HTA models for Alzheimer’s treatments be cross-validated?
- › How sensitive are results to treatment discontinuation and waning efficacy assumptions?
- › What impact does the choice of clinical trial outcome have on model predictions?
- › How can transparency and credibility be improved in Alzheimer’s disease economic models?
References & sources
Similar by meaning
- ICER Value Assessment Framework
- HEcoPerMed Modeling Case Studies for Validation of Methodological Guidance
- HEcoPerMed Guidance for Harmonisation and Improvement of Economic Evaluations in Personalised Medicine
- PACBOARD (Probabilistic Analysis Check dashBOARD)
- Conceptualizing a Model (ISPOR-SMDM Modeling Good Research Practices Task Force-2)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.